Future Journal of Pharmaceutical Sciences最新文献

{"title":"Overutilization of pharmacological venous thromboembolism prophylaxis among medical and surgical critically Ill patients: A retrospective observational cohort study","authors":"Sarah Sabry,&nbsp;Ahmed Essam Abou Warda,&nbsp;Hekmat M. El Magdoub,&nbsp;Doaa H. EL-Farook,&nbsp;Nada Saad Allah,&nbsp;Sayed Gaber,&nbsp;Mai K. Ammar,&nbsp;Manal Abouelkheir","doi":"10.1186/s43094-026-00961-4","DOIUrl":"10.1186/s43094-026-00961-4","url":null,"abstract":"<div><h3>Background</h3><p>Venous thromboembolism (VTE) is a major cause of morbidity among critically ill patients. While most existing evidence highlights the <i>underuse</i> of thromboprophylaxis, the overutilization of pharmacologic VTE prophylaxis in patients who do not meet guideline-based eligibility criteria remains underexplored, despite its potential clinical and economic consequences.</p><h3>Objective</h3><p>To evaluate the clinical outcomes and economic burden of the inappropriate overutilization of pharmacologic VTE prophylaxis among medical and surgical ICU patients.</p><h3>Methods</h3><p>A retrospective observational, single-center study included adult medical and surgical ICU patients who received pharmacological VTE prophylaxis. VTE risk was assessed using the Padua score for medical patients and the Caprini score for surgical patients. Overutilization (inappropriate thromboprophylaxis) was defined as the administration of pharmacological VTE prophylaxis to patients who did not meet guideline-based eligibility criteria. Clinical adverse events and the pharmacoeconomic burden of the inappropriate overutilization were evaluated.</p><h3>Results</h3><p>A total of 330 patients were included (271 medical and 59 surgical). Among both groups, 89.83% of surgical patients and 67.89% of medical patients were classified as high risk for VTE. Inappropriate thromboprophylaxis was observed in 28.18% of patients, more prevalent among medical than surgical patients [32.10% vs. 10.17%, (<i>p</i> = 0.004)]. Patients who received prophylaxis inappropriately had significantly higher rates of bleeding [29% vs. 13.5%, (<i>p</i> &lt; 0.001)], longer ICU stays (Mean ± SD) [7.4 ± 7.1 vs 4.6 ± 5.4, (<i>p</i> &lt; 0.001)]. Inappropriate prophylaxis increased the cost of hospital stays due to bleeding (Mean EGP ± SD) [1231 ± 2016 vs 646 ± 1580, (<i>p</i> = 0.004)] than those who received appropriate prophylaxis.</p><h3>Conclusions</h3><p>Overutilization of pharmacologic VTE prophylaxis among ICU patients was common, reflecting a tendency toward routine initiation of prophylaxis irrespective of risk stratification. The associated economic burden underscores the need for implementing anticoagulant stewardship programs, which could enhance patient safety and optimize resource utilization. Future multicenter studies are necessary to validate these findings. Clinicaltrial.gov Registry: NCT06539156.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00961-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147606725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of UV analytical method and anova application in evaluating Dapagliflozin propanediol monohydrate and teneligliptin hydrobromide hydrate","authors":"Ajumal Hassanar,&nbsp;Sheeja Velayudhan Kutty,&nbsp;Swapna Angadithottunkal Surendran,&nbsp;Yellina Haribabu,&nbsp;Amala Ashokan,&nbsp;Anjali Aravind,&nbsp;Dhithi Vadakkeppat Santhosh,&nbsp;Muhamed Absher","doi":"10.1186/s43094-026-00970-3","DOIUrl":"10.1186/s43094-026-00970-3","url":null,"abstract":"<div><h3>Background</h3><p>Dapagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), and teneligliptin, an inhibitor of dipeptidyl peptidase-4 (DPP-4), are two important oral anti-diabetic medications that are commonly used to treat type 2 diabetes mellitus. By providing different modes of action, these drugs enhance glucose regulation and reduce the chance of long-term complications associated with diabetes. This research seeks to develop and validate a dependable UV spectrophotometric method for analyzing dapagliflozin and teneligliptin, ensuring it conforms to ICH regulations with high accuracy and precision. The developed UV method was compared with existing UV approaches using a one-way ANOVA test.</p><h3>Results</h3><h3>Method</h3><p><b>A</b>: The absorption correction spectrophotometric technique is incorporated into the amplitude of the spectra at 224.60 nm for DAPA and 246.60 nm for TENE. In the process, methanol of HPLC purity was used as solvent. Beer's rule applied to DAPA and TENE at concentrations between 4–12 and 8–24 μg/mL, respectively. <b>Method B</b>: The novel spectrophotometric technique of ratio spectra derivative is used to measure the absorbance for DAPA and TENE at 219.60 nm and 254.20 nm, respectively, using HPLC-grade methanol as the solvent. <b>Method C</b>: The first-order derivative spectrophotometric method was created using distilled water as the solvent. Spectral amplitudes were measured at 266 nm for TENE and 231.60 nm for DAPA. The process demonstrated compliance with Beer's law, with concentration ranges of 4–12 μg/mL for DAPA and 8–24 μg/mL for TENE. The developed method is compared to the previously reported method and the analysis produced a p-value of 1 for the UV technique, which is higher than the significance level of 0.05. The null hypothesis is accepted since there is no statistically significant difference between the approaches. The distinct polarity requirements of DAPA and TENE are reflected in the use of distilled water in Method C and HPLC-grade methanol in Methods A and B. Water slightly shifts λmax and increases baseline noise, which was assessed during robustness studies, while methanol enhances solubility and spectral clarity.</p><h3>Conclusion</h3><p>The UV spectrophotometric approach created for dapagliflozin and teneligliptin has shown itself to be accurate, dependable and cost-effective; it meets all ICH standards for analytical technique validation. This technology provides a dependable approach for routine quality monitoring by making it simpler to quantify these drugs concurrently in pharmaceutical compositions. The one-way ANOVA test conducted demonstrated significant finding.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00970-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147606800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant therapies for postoperative pain management in cesarean section: A comprehensive review of clinical evidence","authors":"Rawan Kamel El Halawani,&nbsp;Eman Mohamed Elmokadem,&nbsp;Khaled Samir Ismael,&nbsp;Hayam Ateyya","doi":"10.1186/s43094-026-00956-1","DOIUrl":"10.1186/s43094-026-00956-1","url":null,"abstract":"<div><h3>Background</h3><p>Cesarean section is among the most commonly performed surgical procedures worldwide, and effective postoperative pain management is essential for promoting early ambulation, breastfeeding, maternal–infant bonding, and overall recovery. Although opioids remain effective for post-cesarean analgesia, their use is associated with maternal and neonatal adverse effects, driving increasing interest in opioid-sparing multimodal analgesic strategies incorporating adjuvant therapies.</p><h3>Main body</h3><p>This narrative review synthesizes and critically evaluates the clinical evidence supporting pharmacological and non-pharmacological adjuvant therapies for postoperative pain management following cesarean section. Emphasis is placed on agents that target complementary pain pathways, including peripheral inflammation, oxidative stress, and central sensitization. Pharmacological adjuvants such as non-steroidal anti-inflammatory drugs, α2-adrenergic agonists, neuromodulators, antioxidants, and emerging immunomodulatory agents are discussed with respect to their mechanisms of action, analgesic efficacy, opioid-sparing potential, and safety profiles in lactating mothers. Non-pharmacological interventions and multimodal combination strategies within enhanced recovery after cesarean section protocols are also reviewed. Emerging evidence supporting novel agents, including endogenous and nutraceutical-based therapies such as lactoferrin, is highlighted.</p><h3>Conclusion</h3><p>Multimodal analgesia incorporating evidence-based adjuvant therapies represents an effective and patient-centered approach to post-cesarean pain management, enabling improved analgesia while minimizing opioid exposure. Selection of adjuvants should be guided by clinical efficacy, safety during lactation, and impact on functional recovery. Further high-quality randomized trials are needed to establish standardized protocols and to clarify the role of emerging adjuvant agents in optimizing post-cesarean analgesic outcomes.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00956-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147606740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serological, molecular, and antimicrobial susceptibility surveillance of Brucella species in Egypt","authors":"Mayada Hammam,&nbsp;Reham Samir,&nbsp;Inass El-Gaafarawi,&nbsp;Khalid Abou-Gazia,&nbsp;Marwa ElRakaiby","doi":"10.1186/s43094-026-00960-5","DOIUrl":"10.1186/s43094-026-00960-5","url":null,"abstract":"<div><h3>Background</h3><p>Brucellosis, an endemic zoonotic infection in Egypt, presents a significant public health concern. This study aimed to identify <i>Brucella</i> isolates from animal and human samples collected from six governorates using serological, bacteriological, and molecular methods. The susceptibility of the isolates to selected antibiotics was also evaluated.</p><h3>Results</h3><p>Serological testing revealed positive brucellosis in 86.8% of human and 4.7% animal sera. 54 suspected <i>Brucella</i> isolates were recovered from human and animal samples. <i>Brucella melitensis</i> was the predominant species followed by <i>Brucella abortus</i>, which were molecularly confirmed using (<i>bcsp31</i>). The isolates harbored key virulence genes of <i>Brucella</i> (<i>bvfA</i>, <i>virB</i>, and <i>ure</i>) and the RNA polymerase-<i>rpoB</i> gene. The isolates expressed overall susceptibility to standard antibiotics used to treat brucellosis, while exhibiting resistance to ceftriaxone, cefotaxime, rifampicin, tetracycline, and linezolid.</p><h3>Conclusions</h3><p>Serological testing proved to be the most practical and rapid detection method for large-scale screening in developing countries, while molecular analysis identified <i>Brucella melitensis</i> to be the predominant species, with the presence of key virulence genes in some isolates. Traditionally prescribed antibiotics remain effective against brucellosis; however, special care should be taken due to the emergence of resistant isolates. Tigecycline and linezolid showed that they can serve as potential alternatives in combination treatments. This study provides a broader, more comprehensive multi-governorate perspective on brucellosis in Egypt offering insights for future surveillance.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00960-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147606739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunomodulatory and anti-inflammatory effects of oleuropein-standardized olive leaf extract in viral infections: a randomized controlled pilot study","authors":"Shimaa M. Abdelgawad,&nbsp;Enas S. Farhat,&nbsp;Radwa A. Elhefny,&nbsp;Mostafa A. Ezzat,&nbsp;Engy A. Wahsh","doi":"10.1186/s43094-026-00958-z","DOIUrl":"10.1186/s43094-026-00958-z","url":null,"abstract":"<div><h3>Background</h3><p>Despite advances in antiviral therapies, effective supportive treatments that reduce inflammation and enhance host immune responses remain an important unmet need in systemic viral infections such as COVID-19. Standardized Olive Leaf Extract (SOLE), rich in oleuropein, has demonstrated antiviral, anti-inflammatory, and immunomodulatory properties in preclinical studies. This pilot randomized clinical trial aimed to explore the potential role of SOLE as an adjunct to standard care, with particular emphasis on clinical symptoms and selected inflammatory and immune biomarkers in patients with mild to moderate COVID-19.</p><h3>Methods</h3><p>This randomized, double-blind, placebo-controlled pilot study enrolled adult patients with laboratory-confirmed mild to moderate COVID-19. Participants were randomly assigned (1:1) to receive either SOLE capsules (750 mg, standardized to 50% oleuropein; 375 mg oleuropein) or matching placebo twice daily for 10 days, in addition to standard treatment. Primary outcomes included viral clearance assessed by RT-PCR and changes in inflammatory and immune parameters, including lactate dehydrogenase (LDH) levels and lymphocyte count.</p><h3>Results</h3><p>A total of 49 patients completed the intervention period. No statistically significant difference in viral clearance was observed between the SOLE and placebo groups (<i>P</i> = 0.296). However, preliminary data suggested that patients receiving SOLE tended toward earlier resolution of several clinical symptoms, including headache (<i>P</i> = 0.001), dyspnea (<i>P</i> &lt; 0.001), and fever (<i>P</i> = 0.01). In addition, SOLE supplementation was associated with a significant increase in lymphocyte count compared with placebo (<i>P</i> = 0.002) and a significant reduction in LDH levels (<i>P</i> = 0.038), suggesting a favorable immunomodulatory and anti-inflammatory effect.</p><h3>Conclusion</h3><p>In this pilot study, standardized olive leaf extract rich in oleuropein did not demonstrate a direct antiviral effect but was associated with meaningful improvement in clinical symptoms and modulation of key inflammatory and immune markers. These findings suggest that SOLE may serve as a supportive adjunctive therapy to alleviate the inflammatory and symptomatic burden of viral infections. Larger studies are warranted to confirm these preliminary observations and further clarify the clinical relevance of oleuropein-mediated immune modulation.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00958-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging clinical and pharmaceutical approaches to enhance medication adherence: a collaborative narrative review","authors":"Eman Mohamed Elmokadem,&nbsp;Basmala Ashraf Kandeel,&nbsp;Maram Mohamed Mahmoud Aly,&nbsp;Maha Elkayal","doi":"10.1186/s43094-026-00959-y","DOIUrl":"10.1186/s43094-026-00959-y","url":null,"abstract":"<div><h3>Background</h3><p>Medication nonadherence is a pervasive and multifactorial challenge that substantially undermines therapeutic effectiveness, increases morbidity and mortality, and imposes a significant economic burden on healthcare systems. Despite advances in pharmacotherapy, a considerable proportion of patients fail to take medications as prescribed due to a complex interplay of patient-related, therapy-related, healthcare system, and socioeconomic factors. Conventional approaches often address adherence in isolation, overlooking the need for integrated strategies that span both clinical practice and pharmaceutical design.</p><h3>Main body</h3><p>This narrative review synthesizes current evidence on the epidemiology, determinants, and clinical and economic burden of medication nonadherence, while critically examining interventions aimed at improving adherence. Particular emphasis is placed on the synergistic integration of clinical strategies—such as patient education, behavioral and motivational support, regimen simplification, pharmacist-led adherence programs, and digital health technologies—with pharmaceutical formulation and drug delivery innovations. These include taste masking technologies, modified- and long-acting dosage forms, alternative delivery systems, fixed-dose combinations, and personalized formulations designed to align therapy with patient preferences and capabilities. By bridging perspectives from clinical pharmacy and pharmaceutical technology, the review highlights the central role of pharmacists within multidisciplinary adherence frameworks and underscores the value of patient-centered, system-level approaches. Current limitations, including heterogeneity in adherence measurement, variable intervention effectiveness, and challenges in real-world implementation, are also discussed.</p><h3>Conclusion</h3><p>An integrated, patient-centered approach that combines clinical interventions with pharmaceutical formulation and delivery innovations represents a promising strategy to improve medication adherence and optimize therapeutic outcomes. Future efforts should focus on generating robust real-world evidence, leveraging digital and personalized medicine technologies, and strengthening collaborative implementation models to enhance adherence and improve healthcare system efficiency.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00959-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HR-LC/MS/MS and GC–MS-based phytochemical analysis of Nephrolepis exaltata (L.) Schott and its antioxidant and anti-Alzheimer’s activities: in vitro and in vivo studies","authors":"Heba A. Mohamed,&nbsp;Sherifa F. Moustafa,&nbsp;Passent M. Abdel-Baki,&nbsp;Abeer A. A. Salama,&nbsp;Wael M. Aboulthana,&nbsp;Nadia M. Sokkar","doi":"10.1186/s43094-026-00957-0","DOIUrl":"10.1186/s43094-026-00957-0","url":null,"abstract":"<div><h3>Background</h3><p><i>Nephrolepis exaltata</i> (L.) Schott is an ornamental non-flowering plant that is found in tropical and subtropical regions. Some <i>Nephrolepis</i> species have been traditionally used to improve memory. For the first time, this study aims to provide comparative metabolomic profiling of <i>N. exaltata</i> (L.) Schott leaves’(NEL) and underground parts’(NEU) hydro-ethanolic extracts and to investigate their saponifiable and unsaponifiable fractions, antioxidant and anti-Alzheimer's activities using in vitro and in vivo models.</p><h3>Results</h3><p>A total of 61 metabolites were tentatively identified, including phenolic acids, flavonoids, terpenoids, lipids, fatty acids and carotenoids using high-resolution tandem mass spectrometry coupled with high-performance liquid chromatography (HR-LC–MS/MS) in positive and negative ionization modes. Additionally, gas chromatography coupled with mass spectrometry (GC–MS) revealed the presence of fatty acids, sesquiterpenoids, diterpenoids, triterpenoids, and sterols. NEL exhibited the highest total phenolic content (281.35 ± 0.32 mg gallic acid/100 g), total antioxidant capacity (267.32 ± 0.47 mg gallic acid/g), iron reducing power (253.34 ± 0.42 μg/mL), 1,1-Diphenyl-2-picryl-hydrazyl (DPPH) (IC₅₀ 7.10 ± 0.01 µg/mL) and 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) (68.99 ± 0.08%) radical-scavenging activities followed by NEU. The leaves butanol fraction demonstrated the highest in vitro acetylcholinesterase (AChE) inhibitory activity (61.20 ± 0.03%). In lipopolysaccharide (LPS)-induced Alzheimer disease in mice model, NEU significantly improved cognitive function, reduced AChE, Toll-like receptor 4 (TLR4), Nuclear factor kappa β (NF-κβ), Tumor necrosis factor alpha (TNF-α), and Angiotensin type 1 receptor (AT1R1) levels, and upregulated Cannabinoid receptor 1 (CB1) as compared to the LPS group followed by the NEL. In the mice treated with NEU, the cerebral cortex, hippocampus subiculum, fascia dentata, hilus, and striatum exhibited normal histological structures. NEL-treated mice showed no histopathological changes in the cerebral cortex and hippocampus subiculum. However, the fascia dentata and hilus exhibited minimal nuclear pyknosis and neuronal degeneration. Moreover, the striatum showed diffuse gliosis between the intact neurons.</p><h3>Conclusion</h3><p>The study reports for the first time 2 important investigations and findings: first, the metabolomic profile in NEL and NEU hydro-ethanolic extracts using HR-LC/MS/MS and GC–MS, and second, the pharmacological evidence of <i>N. exaltata</i> (L.) ability to protect against AD in a mice model.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00957-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical pharmacists’ interventions, resistance, and training needs in ICUs: a FASTHUG-MAIDENS cross-sectional study","authors":"Amani M. Ali,&nbsp;Asia S. Toukhy,&nbsp;Salwa S. Abougalambou","doi":"10.1186/s43094-026-00955-2","DOIUrl":"10.1186/s43094-026-00955-2","url":null,"abstract":"<div><h3>Introduction</h3><p>To standardize and optimize daily patient assessment, many intensive care unit (ICU) clinical pharmacists worldwide have adopted FASTHUG-MAIDENS, a comprehensive mnemonic that guides systematic evaluation of essential care domains, including Feeding, Analgesia, Sedation, Thromboprophylaxis, Hyper/hypoactive delirium, Ulcer prophylaxis, Glucose control, Medication reconciliation, Antibiotics, Indications for medications, Drug dosing, Electrolytes, No drug interactions/allergies, and Stop dates. However, despite its recognized value, pharmacists may still encounter interprofessional resistance and face training gaps that hinder optimal patient care.</p><h3>Aim</h3><p>The objective of this study was to evaluate the key areas of ICU clinical pharmacist interventions, identify interprofessional resistance, and explore training needs within the context of the FASTHUG-MAIDENS checklist.</p><h3>Methods</h3><p>A cross-sectional survey was conducted in December 2024 using a self-administered online questionnaire distributed to ICU clinical pharmacists across Egypt. Descriptive statistics and Kendall’s tau-b correlation test were used to analyze the data, with a <i>p</i>-value &lt; 0.05 considered significant.</p><h3>Results</h3><p>Of the 121 ICU clinical pharmacists surveyed, most were female (76%), under 35 years of age, and working in public hospitals, with nearly two-thirds having less than five years of experience. Across all 14 mnemonic components, interprofessional resistance was most frequently encountered in sedation, antimicrobial therapy, medication indication, and stop-date domains. The highest reported training needs were in feeding, sedation, and delirium management. A significant positive correlation was observed between perceived training needs and the frequency of encountering resistance (r = 0.655, <i>p</i> &lt; 0.001).</p><h3>Conclusion</h3><p>Targeted education, particularly in sedation, delirium management, and nutrition, combined with strategies to address interprofessional barriers is essential to maximize pharmacists’ impact on patient care.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00955-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, synthesis, and multitarget evaluation of novel quinolone-based heterocyclic derivatives as acetyl cholinesterase inhibitors for Alzheimer’s disease therapy","authors":"Anjali M. Dobariya,&nbsp;Vipul M. Vaghela,&nbsp;Sheetal Buddhadev,&nbsp;Bhupendra Prajapati","doi":"10.1186/s43094-026-00967-y","DOIUrl":"10.1186/s43094-026-00967-y","url":null,"abstract":"<div><h3>Background</h3><p>Alzheimer disease is progressive neurodegenerative disorder with mild memory loss and cognitive impairment. Neurodegenerative diseases in which the decrease in the acetylcholine is observed are growing worldwide. Ten quinolone containing compounds were synthesized and screened for acetylcholine inhibition and Aβ fibril formation inhibition.</p><h3>Materials and methods</h3><p>The newly developed compounds were synthesized. Numerous methods (IR, NMR, Mass spectroscopy, etc.,) were used to characterize these substances. In silico study was performed for receptor–drug interaction with acetylcholine and Aβ fibril protein, and ADMET prediction was done for drug-like properties. In vitro Ellman assay and in vivo screening of synthesized compounds were done by using different animal model.</p><h3>Results</h3><p>Anticholinesterase screening results identified compounds D1 and D6 as the most effective of the series. It is the most effective compound screened for vivo studies. The results of molecular docking revealed significant interactions at the active site of cholinesterase Val294, Phe296, Phe297, Typ33, His287, and Aβ fibril protein; the outcomes were good and in agreement with in vivo findings.</p><h3>Conclusion</h3><p>The study’s findings showed that some substances had promising anti-Alzheimer’s properties that were comparable to those of the standard drug. The highly active novel anti-Alzheimer analogues may therefore represent a possible lead, and additional studies may result in a potential new drug candidate.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00967-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro and in vivo characterization of clotrimazole-loaded poly-Ɛ-caprolactone nanocapsules for cutaneous candidiasis","authors":"Ali M. Nasr,&nbsp;Amira Abdel Motaal,&nbsp;Shadeed Gad,&nbsp;Mamdouh Ghorab,&nbsp;Heba A. Ghanem,&nbsp;Hend A. Kamel,&nbsp;Dina Mansour,&nbsp;Sara A. Elmeligy,&nbsp;Fatma ElZahraa A. Ibrahim,&nbsp;Nashwa H. Abd Elwahab","doi":"10.1186/s43094-026-00952-5","DOIUrl":"10.1186/s43094-026-00952-5","url":null,"abstract":"<div><h3>Background</h3><p>One major obstacle facing the medical community in treating skin infections is the growing emergence of Candida species resistance to conventional medications. A Carbopol-based gel containing embedded clotrimazole nanocapsules (CLO-NCs) has recently been suggested as a way to improve the efficacy of topical treatment of cutaneous candidiasis.</p><p>The technique of nanoprecipitation was used to create CLO-NCs. The physicochemical characteristics of the produced CLO-NCs were examined and optimized, including transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), zeta potential (ZP), entrapment efficiency (%EE), and particle size (PS). Evaluations were conducted on in vitro release, skin penetration, in vitro antifungal assay, and in vivo efficacy against infected rats.</p><h3>Results</h3><p>The optimized CLO-NCs showed PS of 226.7 ± 0.17 nm, ZP − 58.2 ± 0.23 mV, and % EE 89.83 ± 0.76%. Additionally, CLO-NC gel showed pseudoplastic rheological behavior, pH, and spreadability. Notably, the permeation of CLO-NCs gel showed a twofold enhancement compared to CLO gel. Crucially, CLO-NC gel’s antifungal activity was 2.24 times greater in an in vitro antifungal assay than in CLO gel. Research conducted in vivo revealed that the treatment period for the animal group receiving CLO-NC gel was shortened by 1.5 times.</p><h3>Conclusion</h3><p>Thus, research showed that CLO-NCs may be an effective drug delivery system with good antifungal capability and increased penetration.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00952-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147561380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}